Ensign Peak Advisors Inc Decreases Holdings in Novo Nordisk A/S (NYSE:NVO)

Ensign Peak Advisors Inc lowered its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 40.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 469,351 shares of the company's stock after selling 314,386 shares during the period. Ensign Peak Advisors Inc's holdings in Novo Nordisk A/S were worth $40,374,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. M. Kulyk & Associates LLC grew its position in shares of Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock worth $274,000 after purchasing an additional 119 shares in the last quarter. Center for Financial Planning Inc. grew its holdings in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Tradewinds Capital Management LLC grew its holdings in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after buying an additional 124 shares in the last quarter. Exencial Wealth Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock worth $1,987,000 after buying an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after buying an additional 126 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.4 %

Shares of NVO opened at $65.75 on Friday. The company's fifty day simple moving average is $69.21 and its 200-day simple moving average is $86.03. The company has a market cap of $295.06 billion, a P/E ratio of 19.98, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. As a group, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on NVO. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Finally, Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating for the company. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.